doi:10.3969/j.issn.1673-8640.2023.11.019

Abstract

CLC Number:

R446.7

Figures/Tables 3

References 12

[1]	TALLMAN M S. Treatment of relapsed or refractory acute promyelocytic leukemia[J]. Best Pract Res Clin Haematol, 2007, 20(1):57-65. DOI URL
[2]	SOIGNET S L. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia[J]. Oncologist, 2001, 6(Suppl 2):11-16. DOI URL
[3]	ZHOU J, ZHANG Y, LI J, et al. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia[J]. Blood, 2010, 115(9):1697-1702. DOI PMID
[4]	MATHEWS V, GEORGE B, CHENDAMARAI E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia:long-term follow-up data[J]. J Clin Oncol, 2010, 28(24):3866-3871. DOI URL
[5]	GHAVAMZADEH A, ALIMOGHADDAM K, ROSTAMI S, et al. Phase Ⅱ study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia[J]. J Clin Oncol, 2011, 29(20):2753-2757. DOI URL
[6]	中华医学会血液学分会, 中国医师协会血液科医师分会. 中国急性早幼粒细胞白学病诊疗指南(2014年版)[J]. 中华血液学杂志, 2014, 35(5):475-477.
[7]	DESANGLES F, VILAIN E, ARBORIO M, et al. t(15;17) hypergranular acute promyelocytic leukemia(M3) developing into a t(3;6) M3 without t(15;17) at relapse[J]. Leuk Lymphoma, 1995, 19(1-2):185-188. DOI URL
[8]	饶若, 姚红霞, 金丽华, 等. 1例t(15;17)的急性早幼粒细胞白血病复发后核型演变成ins(17;15)的病例报道并文献复习[J]. 临床血液学杂志, 2016, 29(1):55-56.
[9]	任维肖, 陈秀花, 任颜, 等. 急性早幼粒细胞白血病治疗后继发急性髓系白血病部分分化型一例并文献复习[J]. 白血病·淋巴瘤, 2020, 29(9):556-560.
[10]	DE BOTTON S, SANZ M A, CHEVRET S, et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy[J]. Leukemia, 2006, 20(1):35-41. DOI PMID
[11]	AGUNAS-RANGEL F A, CHÁVEZ-VALENCIA V. FLT3-ITD and its current role in acute myeloid leukaemia[J]. Med Oncol, 2017, 34(6):114. DOI URL
[12]	张之南, 郝玉书, 赵永强, 等. 血液病学[M]. 2版. 北京: 人民卫生出版社, 2011.

[1]	ZHOU Ying, REN Yihui, LI Guangming. Serum miR-148a expression in children with autoimmune hepatitis and its correlation with inflammatory factors [J]. Laboratory Medicine, 2023, 38(12): 1130-1134.
[2]	YAN An, GUAN Xuhuizi, YU Tian, MIAO Gang, ZHAO Yanyang. Identification of a new susceptibility gene variant EPB41L4A rs1455421289 in Chinese PTC patients by WES [J]. Laboratory Medicine, 2023, 38(11): 1009-1014.
[3]	GAO Jianchao, WANG Sisi, ZHANG Zhisheng, ZHANG Jingli, LI Xiaoxia, MA Ke, FENG Zhilin, ZHOU Haifeng, WANG Zhanhai. Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206，miR-125 and miR-21 [J]. Laboratory Medicine, 2023, 38(11): 1062-1068.
[4]	ZHU Qian, ZHU Lifang, MA Caiyun, YAO Jie. Relation of serum miR-140-5p and PGC-1α mRNA expression with vascular cognitive impairment in acute ischemic stroke patients [J]. Laboratory Medicine, 2023, 38(11): 1069-1074.
[5]	HUANG Zhongqiang, DAI Di, HOU Tieying, LIN Faquan, LU Zhiming, LIU Xiaoqi, SHEN Minna, WU Jie, ZHANG Pingan, ZHOU Jun, XIAO Yanqun, WANG Hualiang. Multicenter performance evaluation of a 7-microRNA test kit [J]. Laboratory Medicine, 2023, 38(11): 1075-1081.
[6]	XUE Yaze, HE Jin, TANG Shaojun. Roles of serum miR-150-5p and LTBP-2 determinations in evaluating the condition of acute cerebral infarction patients [J]. Laboratory Medicine, 2023, 38(11): 1082-1086.
[7]	GUO Mingri, LI Yuming, LI Yan, SUN Haibai. Difference in identification of non-tuberculous Mycobacterium between microarray chip and multiple homologous sequence [J]. Laboratory Medicine, 2023, 38(10): 909-914.
[8]	ZHOU Jun, LI Liheng, ZHANG Min. Expressions of serum miR-24 and XIAP mRNA in serum of oral adenoid cystic carcinoma patients and relationship with prognosis [J]. Laboratory Medicine, 2023, 38(10): 930-935.
[9]	LI Liangshan, ZHAO Hu, WANG Shiwen. Screening potential prognostic biomarkers of colorectal cancer based on weighted gene co-expression network analysis [J]. Laboratory Medicine, 2023, 38(9): 825-832.
[10]	WANG Wei, ZHANG Zhixin, ZHANG Chuanbao, ZHOU Weiyan, WANG Zhiguo. Establishment of allowable total error，allowable imprecision and allowable bias for 22 endocrine analytes [J]. Laboratory Medicine, 2023, 38(8): 707-712.
[11]	Clinical Laboratory Society of Chinese Association for Rehabilitation Medicine , Molecular Diagnostics Society of Shanghai Medical Association , Tumor Immunology Branch of Shanghai Society for Immunology , Yueyang Hospital of Integrated Traditional Chinese and Western Medicine of Shanghai University of Traditional Chinese Medicine , Shanghai Center for Clinical Laboratory, Clinical Laboratory Society of Chinese Association of Integrative Medicine , Clinical Laboratory Society of Shanghai Anticancer Association , Tumor Markers Society of Shanghai Anticancer Association . Expert consensus on the clinical application of AFP，AFP-L3% and DCP using GALAD and GALAD-like models in hepatocellular carcinoma [J]. Laboratory Medicine, 2023, 38(7): 607-623.
[12]	ZHANG Xin, MA Lijuan. Role of cardiac markers in children [J]. Laboratory Medicine, 2023, 38(6): 505-509.
[13]	LIU Ruili, LI Lanjun, JIA Minlei, WANG Yihui, HAO Weina. Correlation between tumor miR-7-5p and NOVA2 levels and clinical prognosis in cancer tissues of patients with gastric cancer [J]. Laboratory Medicine, 2023, 38(4): 325-329.
[14]	WANG Xin, DENG Qian, WANG Juanjuan, CAI Wenjuan, GAO Jian, HAN Yanping, HU Kefei, CHEN Yuqing. Clinical characteristics and genetic analysis of Desbuquois dysplasia Kim type caused by CANT1 mutation [J]. Laboratory Medicine, 2023, 38(2): 130-136.
[15]	WANG Ruijuan, LI Chao, DUAN Lijuan, SHANG Miao, YANG Ruyu. Expression and clinical significance of lncRNA RBM5-AS1 in acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(1): 39-45.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 12

Related Articles 15

Recommended Articles

Metrics